Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) EBT Margin (2016 - 2026)

Myriad Genetics has reported EBT Margin over the past 17 years, most recently at 4.24% for Q4 2025.

  • Quarterly EBT Margin rose 1432.0% to 4.24% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 47.92% through Dec 2025, down 3319.0% year-over-year, with the annual reading at 47.92% for FY2025, 3318.0% down from the prior year.
  • EBT Margin was 4.24% for Q4 2025 at Myriad Genetics, up from 12.74% in the prior quarter.
  • Over five years, EBT Margin peaked at 23.79% in Q3 2021 and troughed at 155.14% in Q2 2025.
  • The 5-year median for EBT Margin is 17.01% (2023), against an average of 25.21%.
  • Year-over-year, EBT Margin skyrocketed 6076bps in 2021 and then plummeted -13755bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 27.05% in 2021, then decreased by -8bps to 29.3% in 2022, then soared by 44bps to 16.43% in 2023, then fell by -13bps to 18.57% in 2024, then surged by 77bps to 4.24% in 2025.
  • Per Business Quant, the three most recent readings for MYGN's EBT Margin are 4.24% (Q4 2025), 12.74% (Q3 2025), and 155.14% (Q2 2025).